Answers are grounded in this paper and cite their sources.
The transrepression activity of PPAR-α on chronic liver inflammation is sufficient to prevent progression of NASH to liver fibrosis. Dissociated PPAR-α agonists, selectively modulating PPAR-α transrepression activity, could thus be an option to prevent NASH and fibrosis progression.
No takes yet. Share an insight, caveat, or question.
Pawlak et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: